Moderna, IBM to use quantum computing and AI in medical research

 Moderna, a manufacturer of vaccines, has collaborated with IBM to investigate the application of quantum computing and artificial intelligence (AI) to the creation of future mRNA Therapeutics market.

The project aims to design mRNA medicines with optimal performance and safety by combining advanced formulation discovery with generative AI.

Problems that are beyond the capabilities of conventional computers can be resolved using quantum computing, which is based on the principles of quantum mechanics.

Moderna will be able to use IBM's quantum computing systems and expertise as a result of the agreement to investigate potential applications in life science.

The tie-up will see Moderna participate in the IBM Quantum Gas pedal program and the IBM Quantum Organization.

MoLFormer, an AI foundation model developed by IBM and Moderna scientists, will also be used to better comprehend the characteristics of potential mRNA medications.

Stéphane Bancel, the CEO of Moderna, said: We are thrilled to collaborate with IBM to develop novel AI models to advance mRNA research, prepare for the quantum computing era, and prepare our company for these game-changing technologies.

Daro Gil, senior vice president and director of IBM Research, stated: Moderna will be able to benefit from our multi-year research on generative AI for therapeutics, which can help scientists learn more about how molecules behave and make it easier to make completely new molecules.

Comments

Popular posts from this blog

Exploring Ecopetrol's Key Locations: A Comprehensive Guide

Understanding the Competitive Landscape of BlackBerry Ltd.

Understanding Aflac's Growth: A Financial Analysis of the Last Quarter